Camilla V. Simpson net worth and biography

Camilla Simpson Biography and Net Worth

Director of Spruce Biosciences

Camilla V. Simpson holds the position of President & Managing Member at Rare Strategic LLC.

She is also on the board of Spruce Biosciences, Inc., Aristea Therapeutics, Inc. and Dyve Biosciences, Inc.

In the past Ms. Simpson held the position of Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. and Vice President-Regulatory Affairs for Shire Pharmaceuticals, Inc.

Camilla V. Simpson received an undergraduate degree from Kingston University, an undergraduate degree from National University of Ireland Galway and a graduate degree from Birkbeck University of London.

What is Camilla V. Simpson's net worth?: The estimated net worth of Camilla V. Simpson is at least $22.01 as of May 20th, 2021. Ms. Simpson owns 334 shares of Spruce Biosciences stock worth more than $22 as of May 13th. This net worth evaluation does not reflect any other assets that Ms. Simpson may own. Learn More about Camilla V. Simpson's net worth.
How do I contact Camilla V. Simpson?: The corporate mailing address for Ms. Simpson and other Spruce Biosciences executives is , , . Spruce Biosciences can also be reached via phone at 415-655-4168 and via email at investors@sprucebiosciences.com. Learn More on Camilla V. Simpson's contact information.
Has Camilla V. Simpson been buying or selling shares of Spruce Biosciences?: Camilla V. Simpson has not been actively trading shares of Spruce Biosciences during the past quarter. Most recently, Camilla V. Simpson sold 334 shares of the business's stock in a transaction on Thursday, May 20th. The shares were sold at an average price of $15.29, for a transaction totalling $5,106.86. Following the completion of the sale, the director now directly owns 334 shares of the company's stock, valued at $5,106.86. Learn More on Camilla V. Simpson's trading history.

Camilla V. Simpson Insider Trading History at Spruce Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/20/2021	Sell	334	$15.29	$5,106.86	334
4/30/2021	Sell	14,045	$16.14	$226,686.30	14,045

Camilla V. Simpson Buying and Selling Activity at Spruce Biosciences

Spruce Biosciences Company Overview

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $0.07

$0.06

$0.07

50 Day Range

MA: $0.23

$0.07

$0.36

2 Week Range

Now: $0.07

$0.06

$0.85

Volume

224,701 shs

Average Volume

736,812 shs

Market Capitalization

$2.78 million

P/E Ratio

N/A

Dividend Yield